Pfizer shelves obesity pill plan after patient suffers liver injury during clinical trial ()

logo
FirstPost Health
· 1 day ago
Pfizer shelves obesity pill plan after patient suffers liver injury during clinical trial

Pfizer Inc. has said it will discontinue development of its closely watched obesity pill, danuglipron, dealing a severe blow to the company’s ambitions to compete in the rapidly growing weight-loss drug market dominated by Novo Nordisk and Eli Lilly, according to a report

banner

Continue reading